Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move
(TSXV: $KHRN.V) (OTCQB: $KHRNF), (CSE: $MYM.C) (OTCBB: $MYMMF)
(NASDAQ: $OGI)
Also featured in today’s potcast- (CSE: $HUGE.C) (OTCQB: $FSDDF)
(TSXV: $OGI.V), (TSX: $IN.TO) (OTCQX: $IMLFF)
Delta, Kelowna, BC –July 2,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07021KHRN-MYM-OGI.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
Today we are looking at a few early
announcements.
But first, Health Minister Simon Harris signed
legislation which will now allow Irish citizens
access to cannabis-based products for medical use on a pilot basis for five
years. The new Medical
Cannabis Access Programme allows medical
consultants to prescribe medicinal cannabis of a standardised quality to
patients who have failed to respond to standard treatments.
Minister Harris first
proposed the programme two years ago, but its passage through the Dáil was delayed amid problems finding a
quality-assured supplier of medicinal cannabis able to export its products to
Ireland.
Earlier this year, it was confirmed that a
supplier had been identified and the legislation was finally signed this
morning.
The new scheme will facilitate access to
medical cannabis for patients with the following conditions if they have failed
to respond to standard treatments:
● Spasticity associated with multiple
sclerosis
● Intractable nausea and vomiting associated
with chemotherapy
● Severe, refractory (treatment-resistant)
epilepsy
Commenting on the launch today, Mr Harris
said: "It is important to state that there are no plans to legalise
cannabis in this country.
"The purpose of this programme is to
facilitate compassionate access to cannabis for medical reasons, where
conventional treatment has failed.
"Ultimately it will be the decision of
the medical consultant, in consultation with their patient, to prescribe a
particular treatment, including a cannabis-based treatment, for a patient under
their care."
Previously, there were no medical cannabis
products available in Ireland and many sufferers were forced to spend thousands
each year to access cannabis-based treatments in countries such as the
Netherlands.
The new legislation means that commercial
operators whose cannabis products meet the specified requirements will be able
to supply products to the Irish market.
The Medical Cannabis Access Programme will
operate on a pilot basis for five years before a review in 2024.
Khiron Life
Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF), commented on the EU-Mercosur Trade Agreement announced
between the European Union and Mercosur, the Latin American trading block made
up of Argentina, Brazil, Uruguay and Paraguay. Khiron is active among Mercosur
jurisdictions with a recently completed acquisition of NettaGrowth
International, a cannabis company based in Uruguay.
The
trade deal between the European Union and Mercosur announced on June 28, 2019
at the G20 Summit in Japan, which is subject to ratification by member
countries, establishes a trade framework for goods and services, including
pharma and medical products, covering nearly 780 million consumers, making it the
largest in the world in terms of population, and with an estimated trade in
goods of 88 Billion Euros (Source: European Commission).
Alvaro
Torres, Khiron CEO and Director, comments "As we build Khiron's dominant
position in Latin America and Mercosur markets through our operations in
Uruguay, we welcome this trade deal as it strengthens our ability to now
directly supply the European medical cannabis market. This significant
milestone is another step towards a globalized medical cannabis trade network
where Latin America, with its strategic location, many natural advantages and
regulatory leadership, will continue to play a significant part."
Khiron
announced completion of the acquisition of NettaGrowth International on June
19, 2019. NettaGrowth, and its wholly-owned subsidiary Dormul S.A. is a
Uruguayan company that has obtained one of the first licences to produce and
export medical cannabis with THC for commercialization in Uruguay, and is
positioned to serve Brazil and the growing Latin American market as part of the
Mercosur trading block, adopting the Company's scalable model as markets
develop.
MYM Nutraceuticals
Inc. (CSE: MYM) (OTCBB: MYMMF) announced that its subsidiary in Colombia, Colombia
Organica S.A.S, has signed agreements in principle to cultivate both THC and
CBD-rich cannabis with independent farmers for an initial five acres.
Cannabis
will be cultivated by farmers who will be licensees under the existing Colombia
Organica cannabis cultivation licenses. The first crops cultivated on the
initial five acres will function as test crops with the intention to add
subsequent acreage. The climate in Colombia is ideal for cultivating cannabis,
with the growing season being year-round it's possible to harvest three crops
of THC or CBD-rich cannabis annually.
"Our
team in Colombia has begun to execute on our plan to cultivate both THC and
CBD-rich cannabis in South America," said Howard Steinberg, CEO of MYM.
"The strategy of extending our licenses to neighbouring farmers to
cultivate cannabis will serve to increase our biomass supply that we intend on
processing and exporting to the global market."
Colombia
Organica is committed to extending its licenses to the independent farmers for
an initial period of five years. The farmers will be responsible for all costs
associated with cultivation from seed to sale. Colombia Organica agrees to
purchase the harvested biomass at a price to be determined at the time of
delivery based on the average market price at that time.
MYM
is currently finalizing the closing documents that will see its own 80% of
Colombia Organica.
Organigram Holdings
Inc. (NASDAQ: OGI) (TSXV: OGI), the parent company of Organigram Inc., a
leading licensed producer of cannabis, announced today it will report its third quarter earnings
results for its fiscal year ended August 31, 2019 on Monday, July 15, 2019
before market open.
The
Company will host a conference call to discuss its third quarter 2019 earnings
results at 8am EST.
A replay of the webcast will be available
within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the
call.
FSD Pharma Inc. (CSE:HUGE) (OTCQB:
FSDDF) and Prismic Pharmaceuticals Inc., a
U.S.-based specialty R&D pharmaceutical company, have
announced that, on June 28, 2019, they finalized
the acquisition by FSD Pharma of all of the issued and outstanding securities
of Prismic for an aggregate purchase price of approximately US$17.5 million,
satisfied by the issuance of approximately 102.7 million Class B subordinate
voting shares in the capital of FSD Pharma at a deemed price of CAD$0.2275 per
FSD Share. In addition, FSD Pharma has agreed to assume approximately US$3.05
million of outstanding Prismic long- and short-term liabilities.
FSD Pharma will continue to be led by
Raza Bokhari, MD, executive co-chairman and CEO. Zachary Dutton, co-founder of
Prismic, will continue to serve as the CEO of Prismic, reporting to Edward
Brennan, Jr. MD, FACS, president of the FSD Biosciences Division.
Peter Moriarty, co-founder and previous
chairman of the board of Prismic, has been named chairman of the newly-formed
FSD BioPharmaceutical Industry Advisory Board.
Bokhari stated, “On behalf of the FSD
Pharma shareholders and Board of Directors, it is with immense pleasure that I
welcome Prismic shareholders and stakeholders to the FSD Pharma family. Over
the past several weeks, Dr. Brennan and our M&A team have worked very
closely with the Prismic leadership to finalize this transaction under budget
and ahead of schedule. I must commend Dr. Brennan on his laser sharp focus and
attention to detail and I must also express my special gratitude to Zach Dutton
and Peter Moriarty for their efforts in resolving some outstanding issues to
close the transaction.”
Bokhari continued, “The Prismic
acquisition represents strategic depth in the vision and mission of FSD Pharma
and signals a paradigm shift in the overall outlook of the company. We are
relying heavily on the expertise of Dr. Brennan, who is a seasoned
pharmaceutical industry veteran with substantial experience from working at
Glaxo Smith Kline and Johnson & Johnson to navigate us through the various
stages of the FDA approval process for drug development, with the goal of
eventually making synthetic cannabinoid prescription medications available for
commercial use to help alleviate the pain and suffering of patients. We are
confident, Peter Moriarty, another well-known pharmaceutical industry veteran,
who was also one of the founders of Shire Pharmaceuticals, will make a
meaningful contribution to the FSD Pharma story as the chairman of the
BioPharmaceutical industry advisory board.”
InMed Pharmaceuticals Inc. (TSX:IN) (OTCQX:IMLFF), a
biopharmaceutical company developing a proprietary biosynthesis technology for
cannabinoid-based pharmaceuticals to treat severe diseases, today
announced the appointment of Catherine Sazdanoff,
JD, to its Board of Directors.
Ms. Sazdanoff joins InMed's Board with 35
years of experience in the healthcare industry. She held various global VP
roles in business development and corporate development at Takeda
Pharmaceuticals, which she joined in 2006. Prior to Takeda, Ms. Sazdanoff
served in senior global legal and pharmaceutical business roles at Abbott
Laboratories since 1984, including litigation, international commercial and
transactional legal roles, marketing, and business development. At both
companies, she completed numerous collaborations and transformational M&A
transactions, including Abbott's acquisition of Knoll Laboratories (including
the mega-blockbuster drug Humira®), and Takeda's acquisition of Millennium
Pharmaceuticals and Nycomed S.A.
Ms. Sazdanoff is an independent director
of the Board of Meridian Bioscience,
Inc. (NASDAQ:
VIVO). She is currently President and CEO of
Sazdanoff Consulting LLC, where she acts as Business Advisor to Strata
Oncology, Inc., a private precision oncology company, and works with other
healthcare companies on strategy and corporate/business development. Ms.
Sazdanoff has a BA in English from the University of Notre Dame, and a JD from
Northwestern University School of Law.
"We are enthusiastic to welcome
Catherine to our Board of Directors at an exciting time in the Company's
evolution," commented Eric A. Adams, President and Chief Executive
Officer. "Her diverse business development and legal experience, built
from over 35 years in the pharmaceutical industry, will be important as we
accelerate the development of our therapeutic pipeline and scale-up our
innovative biosynthesis platform technology. Importantly, Catherine's rich
experience in pharma deal making will be highly beneficial to InMed as our
assets mature and we begin strategizing about potential transactions."
"InMed has unique opportunities to
bring significant medical advances to important patient populations with its
differentiated cannabinoid-based therapeutic pipeline and novel biosynthesis
manufacturing technology," stated Ms. Sazdanoff. "I am delighted to
join the team and look forward to working closely with the Company's management
as InMed drives towards long-term value creation."
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment